Dihydroorotate Dehydrogenase

An oxidoreductase that catalyzes the conversion of DIHYDROOROTATE to orotate with QUINONE as an electron acceptor in the biosynthesis of PYRIMIDINES.

Also Known As:

DHODase A; DHODase B; A, DHODase; B, DHODase; C Reductase, Dihydro-Orotate-Cytochrome; DHOO Dehydrogenase U; Dehydrogenase, Dihydro-Orotate; Dehydrogenase, Dihydroorotate; Dihydro Orotate Cytochrome C Reductase; Oxidoreductase, Dihydroorotate-Ubiquinone; Reductase, Dihydro-Orotate-Cytochrome C; DHODH; DHOO-Dehydrogenase-U; Dihydro-Orotate Dehydrogenase; Dihydro-Orotate-Cytochrome C Reductase; Dihydroorotate Dehydrogenase (Ubiquinone); Dihydroorotate Dehydrogenase Type A; Dihydroorotate Dehydrogenase Type B; Dihydroorotate Dehydrogenase Type C; Dihydroorotate-Ubiquinone Oxidoreductase

Networked: 308 relevant articles (22 outcomes, 34 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Enzymes and Coenzymes: 1
- Enzymes: 152586
  - Oxidoreductases: 13671
    - Oxidoreductases Acting on CH-CH Group Donors
      - Dihydroorotate Dehydrogenase: 308

Experts

1.	Phillips, Margaret A: 14 articles (01/2021 - 06/2008)
2.	Deng, Xiaoyi: 11 articles (01/2021 - 09/2009)
3.	El Mazouni, Farah: 10 articles (01/2021 - 06/2008)
4.	Rathod, Pradipsinh K: 10 articles (01/2021 - 06/2008)
5.	White, John: 8 articles (01/2021 - 06/2008)
6.	Boschi, Donatella: 6 articles (06/2022 - 01/2018)
7.	Giorgis, Marta: 6 articles (06/2022 - 01/2018)
8.	Sainas, Stefano: 6 articles (06/2022 - 01/2018)
9.	Huang, Jin: 6 articles (01/2022 - 10/2013)
10.	Burrows, Jeremy N: 6 articles (01/2021 - 06/2014)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2018 - "In vivo preclinical studies demonstrate strong antitumor activity upon DHODH inhibition in a pancreatic tumor xenograft model." 10/01/2023 - "In addition, DPCP achieves sustained degradation of DHODH upon activation by CatB overexpressed in the tumor. " 09/30/2023 - "However, the expression pattern and especially the functional roles of DHODH during cancer cell death are generally unknown. " 08/18/2023 - "Publisher Correction: A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage." 01/01/2023 - "These results suggest that NPD723 is reduced in cells to its active metabolite H-006, which then targets DHODH and suppresses cancer cell growth. "
2.	Malaria 05/24/2018 - "The inhibition of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) potentially represents a new treatment option for malaria, as P. " 12/09/2016 - "A Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitor with Improved Drug-like Properties for Treatment and Prevention of Malaria." 12/20/2022 - "We chemically validate the target by repurposing a unique library of ~450 triazolopyrimidine/imidazopyrimidine analogs developed for our malaria DHODH program to identify 21 compounds with submicromolar activity on AbDHODH. " 09/01/2019 - "DSM421, a dihydroorotate dehydrogenase inhibitor, was in preclinical development as a potential treatment option for malaria. " 01/01/2018 - "Plasmodium falciparum dihydroorotate dehydrogenase: a drug target against malaria."
3.	Autoimmune Diseases (Autoimmune Disease) 06/26/2014 - "Our studies define the requirements for species-selective binding to PfDHODH and show that the triazolopyrimidine scaffold can alternatively be tuned to inhibit human DHODH, an important target for autoimmune diseases." 10/01/2010 - "DHODH is a known target for the treatment of autoimmune diseases. " 11/12/2020 - "Use of Dihydroorotate Dehydrogenase Inhibitors for Treatment of Autoimmune Diseases and Cancer." 10/07/2015 - "Human dihydroorotate dehydrogenase (hDHODH) is an attractive therapeutic target for the treatment of rheumatoid arthritis, transplant rejection and other autoimmune diseases. " 12/05/2020 - "IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro."
4.	COVID-19 01/01/2021 - "There are a number of clinical trials underway for COVID19 treatment using DHODH inhibitors; however, there are only a small number of known DHODH antagonists available for testing. " 12/01/2020 - "However, there are limited data from clinical studies to prove the application of DHODH inhibitors in Coronavirus disease 2019 (COVID-19) patients. " 10/01/2020 - "Dihydroorotate dehydrogenase inhibitors in SARS-CoV-2 infection." 02/01/2022 - "Emvododstat was identified as a potent inhibitor of dihydroorotate dehydrogenase and is now in clinical development for the treatment of acute myeloid leukaemia and COVID-19. " 12/06/2021 - "We aimed to evaluate the efficacy and safety of leflunomide, an approved dihydroorotate dehydrogenase inhibitor, to treat coronavirus disease 2019 (COVID-19) patients with prolonged postsymptomatic viral shedding. "
5.	Melanoma (Melanoma, Malignant) 03/24/2011 - "When used alone or in combination with a specific inhibitor of the BRAF(V600E) oncogene, DHODH inhibition led to a marked decrease in melanoma growth both in vitro and in mouse xenograft studies. " 12/22/2017 - "Our findings provided evidences for the potential of DHODH used as a drug target for melanoma treatment." 12/22/2017 - "Herein, we found that DHODH inactivation/deficiency inhibited melanoma cell proliferation, induced cell cycle arrest at S phase and lead to autophagy in human melanoma cells. " 12/22/2017 - "Inactivation/deficiency of DHODH induces cell cycle arrest and programed cell death in melanoma." 08/17/2017 - "These findings suggest that p38, GR and DHODH are potentially involved in the anti-melanoma action of BBR. "

Related Drugs and Biologics

1.	Dihydroorotate Dehydrogenase
2.	Enzymes
3.	Leflunomide (Arava)
4.	pyrimidine
5.	teriflunomide
6.	emvododstat
7.	orludodstat
8.	brequinar
9.	Proteins (Proteins, Gene)
10.	vidofludimus

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Precision Medicine
4.	Radiotherapy
5.	Chinese Traditional Medicine (Traditional Chinese Medicine)